# Ulcerative Colitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ulcerative-colitis

> 24 upcoming FDA catalysts in ulcerative Colitis: brivekimig (SNY) on Dec 2026 to Mar 2027 (topline data readout); brivekimig (SNY) on December 2026 (primary completion); tilpisertib fosmecarbil (GILD) on January 2027 (primary completion); tilpisertib fosmecarbil (GILD) on Jan to Apr 2027 (topline data readout); and 20 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 30, 2025 | [Nx-13 250mg primary completion](https://sec-api.dev/pdufa/nx-13) | ABBV | Ulcerative Colitis | withdrawn | "NCT05785715 (Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785715)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216)) |
| Dec 2025 | [Rosnilimab topline data readout](https://sec-api.dev/pdufa/rosnilimab) | ANAB | ulcerative colitis | scheduled | "•Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000137005325000088/q32025earningsrelease.htm)) |
| January 2026 | [Rosnilimab primary completion](https://sec-api.dev/pdufa/rosnilimab) | ANAB | Ulcerative Colitis | delayed | "NCT06127043 (A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01 (ESTIMATED); Lead Sponsor AnaptysBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06127043)) |
| March 4, 2026 | [Mirikizumab primary completion](https://sec-api.dev/pdufa/mirikizumab) | LLY | Ulcerative Colitis | completed | "NCT03519945 (A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519945)) |
| March 4, 2026 | [Emvistegrast primary completion](https://sec-api.dev/pdufa/emvistegrast) | GILD | Ulcerative Colitis | completed | "NCT06290934 (Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290934)) |
| April 28, 2026 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05535946 (ABTECT - Maintenance): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05535946)) |
| May 1, 2026 | [Mirikizumab iv primary completion](https://sec-api.dev/pdufa/mirikizumab-iv) | LLY | Ulcerative Colitis | completed | "NCT05784246 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05784246)) |
| July 14, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Ulcerative Colitis | completed | "NCT06254950 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06254950)) |
| August 12, 2026 | [Iv tulisokibart primary completion](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Ulcerative Colitis | completed | "NCT06052059 (A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052059)) |
| Aug to Nov 2026 | [Iv tulisokibart topline data readout](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Ulcerative Colitis | scheduled | "NCT06052059 (A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052059)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203?tab=results)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216?tab=results)) |
| Dec 2026 to Mar 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| December 2026 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| January 2027 | [Tilpisertib fosmecarbil primary completion](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) | GILD | Ulcerative Colitis | scheduled | "NCT06029972 (Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029972)) |
| Jan to Apr 2027 | [Tilpisertib fosmecarbil topline data readout](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) | GILD | Ulcerative Colitis | scheduled | "NCT06029972 (Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029972)) |
| Mar to Jun 2027 | [Xeljanz (tofacitinib citrate) topline data readout](https://sec-api.dev/pdufa/tofacitinib) | PFE | Ulcerative Colitis | scheduled | "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624230)) |
| March 2027 | [Xeljanz (tofacitinib citrate) primary completion](https://sec-api.dev/pdufa/tofacitinib) | PFE | Ulcerative Colitis | scheduled | "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624230)) |
| May 2027 | [Zotemtegrast primary completion](https://sec-api.dev/pdufa/zotemtegrast) | LLY | Ulcerative Colitis | scheduled | "NCT07186101 (LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07186101)) |
| May to Aug 2027 | [Zotemtegrast topline data readout](https://sec-api.dev/pdufa/zotemtegrast) | LLY | Ulcerative Colitis | scheduled | "NCT07186101 (LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07186101)) |
| August 2027 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06880744 (A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880744)) |
| Aug to Nov 2027 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06880744 (A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880744)) |
| September 2027 | [AMJEVITA® (adalimumab) primary completion](https://sec-api.dev/pdufa/adalimumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06257875)) |
| Sep to Dec 2027 | [AMJEVITA® (adalimumab) topline data readout](https://sec-api.dev/pdufa/adalimumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06257875)) |
| March 2028 | [ABX464 primary completion](https://sec-api.dev/pdufa/abx464) | ABVX | Ulcerative Colitis | scheduled | "NCT05177835 (Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05177835)) |
| Mar to Jun 2028 | [ABX464 topline data readout](https://sec-api.dev/pdufa/abx464) | ABVX | Ulcerative Colitis | scheduled | "NCT05177835 (Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05177835)) |
| May to Aug 2028 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07184996 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184996)) |
| May 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07184996 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184996)) |
| August 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Ulcerative Colitis | scheduled | "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05782907)) |
| Aug to Nov 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Ulcerative Colitis | scheduled | "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05782907)) |
| Sep to Dec 2028 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07185009 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185009)) |
| September 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07185009 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185009)) |
| Jun to Sep 2029 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT03950232 (An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03950232)) |
| Jun to Sep 2029 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT05287126 (A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05287126)) |
| June 2029 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT05287126 (A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05287126)) |
| June 2029 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Ulcerative Colitis | scheduled | "NCT03950232 (An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03950232)) |

## Drugs

- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Rosnilimab](https://sec-api.dev/pdufa/rosnilimab) (ANAB)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ulcerative-colitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ulcerative Colitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ulcerative-colitis

```bibtex
@misc{secapidev_indications_ulcerative_colitis_20261116,
  title        = {Ulcerative Colitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ulcerative-colitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ulcerative_colitis_20261116","title":"Ulcerative Colitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ulcerative-colitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
